A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Public ClinicalTrials.gov record NCT03935217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.
Study identification
- NCT ID
- NCT03935217
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 147 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2019 (Actual)
- Primary completion
- Mar 2, 2020 (Actual)
- Completion
- Mar 25, 2020 (Actual)
- Last update posted
- Oct 4, 2023
2019 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 1007 | Birmingham | Alabama | 35294 | — |
| Site 1003 | North Miami | Florida | 33161 | — |
| Site 1014 | Chicago | Illinois | 60605 | — |
| Site 1013 | Jackson | Mississippi | 39216 | — |
| Site 1009 | Lawrenceville | New Jersey | 08648 | — |
| Site 1008 | Chapel Hill | North Carolina | 27599 | — |
| Site 1004 | Fayetteville | North Carolina | 28304 | — |
| Site 1011 | Charleston | South Carolina | 29425 | — |
| Site 1001 | Memphis | Tennessee | 38104 | — |
| Site 1002 | Memphis | Tennessee | 38120 | — |
| Site 1006 | Virginia Beach | Virginia | 23456 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03935217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 4, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03935217 live on ClinicalTrials.gov.